亚甲蓝染料用于乳腺癌淋巴绘图的安全性和技术成功率。
Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer.
作者信息
Zakaria Shaheen, Hoskin Tanya L, Degnim Amy C
机构信息
Department of Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
出版信息
Am J Surg. 2008 Aug;196(2):228-33. doi: 10.1016/j.amjsurg.2007.08.060.
BACKGROUND
We aimed to evaluate the safety and efficacy of methylene blue dye (MBD) for sentinel lymph node (SLN) mapping in breast cancer.
METHODS
A total of 398 patients undergoing 401 SLN biopsy procedures with MBD were retrospectively reviewed and divided into 3 groups based on dye concentration and location of dye injection. Technical success and complication rates were compared.
RESULTS
Overall technical success of SLN biopsy was 99.7%. Technical success of SLN mapping with MBD was lowest in the group receiving full strength dye in a peritumoral location (74%) and highest in the group that received very dilute MBD (1.25 mg/mL) in the subareolar location (92%, P = .004). The complication rate was highest in the first group (21%) and lowest in the latter (2%, P = .0003).
CONCLUSIONS
Dilute MBD (1.25 mg/mL) successfully maps SLNs with very few complications.
背景
我们旨在评估亚甲蓝染料（MBD）用于乳腺癌前哨淋巴结（SLN）定位的安全性和有效性。
方法
对总共398例接受401次使用MBD进行SLN活检手术的患者进行回顾性分析，并根据染料浓度和注射部位分为3组。比较技术成功率和并发症发生率。
结果
SLN活检的总体技术成功率为99.7%。在肿瘤周围部位接受原液染料的组中，使用MBD进行SLN定位的技术成功率最低（74%），而在乳晕下部位接受极稀MBD（1.25 mg/mL）的组中最高（92%，P = 0.004）。第一组的并发症发生率最高（21%），后一组最低（2%，P = 0.0003）。
结论
稀释的MBD（1.25 mg/mL）能成功定位SLN，且并发症极少。
Zotero 插件